Tracing cardiac metabolism in vivo: One substrate at a time

Journal of Nuclear Medicine

Volumn 51, Issue SUPPL.1, 2010, Pages

  Taegtmeyer, Heinrich ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cardiac metabolic imaging; Cardiac structural imaging; Cardiac substrate imaging; Cardiology (basic technical); Molecular imaging; PET MRI

Indexed keywords

ADENOSINE TRIPHOSPHATE; TRACER; FATTY ACID; GLUCOSE; OXYGEN;

AEROBIC METABOLISM; CARDIAC PATIENT; ENERGY TRANSFER; ENZYME SUBSTRATE COMPLEX; FATTY ACID METABOLISM; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HUMAN; IN VIVO STUDY; MUSCLE CONTRACTION; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; CARDIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; HEART; HEART DISEASE; HEART MUSCLE; HEMODYNAMICS; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOLOGY; FATTY ACIDS; GLUCOSE; HEART; HEART DISEASES; HEMODYNAMICS; HUMANS; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MYOCARDIUM; OXYGEN; POSITRON-EMISSION TOMOGRAPHY;

EID: 77953058446     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.068205     Document Type: Review

References (80)

1. Winterstein H. Ueber die Sauerstoffatmung des isolierten Saeugetierherzens. Z Allg Physiol. 1904;4:339-359.
2. Taegtmeyer H. Myocardial energetics: still only the tip of an iceberg. Heart Lung Circ. 2003;12:3-6.
3. Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci. 2004;1015:202-213.
4. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol. 1994;19:59-113.
5. Holmes FL. Between Biology and Medicine: The Formation of Intermediary Metabolism. Berkeley, CA: University of California at Berkeley; 1992:114.
6. Taegtmeyer H, Hems R, Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J. 1980;186:701-711.
7. Katz AM. Molecular biology in cardiology, a paradigmatic shift. J Mol Cell Cardiol. 1988;20:355-366.
8. Taegtmeyer H. Fueling the heart: multiple roles for cardiac metabolism. In: Willerson JT, Cohn JN, Wellens HJJ, Holmes DR, eds. Cardiovascular Medicine. 3rd ed. London, U.K.: Springer-Verlag; 2007:1157-1169.
9. Herrero P, Peterson LR, McGill JB, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 2006;47:598-604.
10. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191-2196.
11. Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol. 2002;34:1259-1271.
12. Baldwin JE, Krebs HA. The evolution of metabolic cycles. Nature. 1981;291:381-382.
13. Taegtmeyer H. Carbohydrate interconversions and energy production. Circulation. 1985;72:1-8.
14. Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16:504-515.
15. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
16. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab. 2009;297:E578-E591.
17. van Bilsen M, Van der Vusse GJ, Reneman RS. Transcriptional regulation of metabolic processes: implications for cardiac metabolism. Pflugers Arch. 1998;437:2-14.
18. Arany Z, He H, Lin J, et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005;1:259-271.
19. Lehman JJ, Boudina S, Banke NH, et al. The transcriptional coactivator PGC-1 alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol. 2008;295:H185-H196.
20. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92:829-839.
21. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106:847-856.
22. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007;115:2540-2548.
23. Evans G. The glycogen content of the rat heart. J Physiol (Lond.). 1934;82:468-480.
24. Denton RM, Randle PJ. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Biochem J. 1967;104:416-422.
25. Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273:29530- 29539.
26. Fisher DJ, Heymann MA, Rudolph AM. Myocardial oxygen and carbohydrate consumption in fetal lambs in utero and in adult sheep. Am J Physiol. 1980;238:H399-H405.
27. Goodwin GW, Taegtmeyer H. Improved energy homeostasis of the heart in the metabolic state of exercise. Am J Physiol Heart Circ Physiol. 2000;279:H1490-H1501.
28. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278:H1345-H1351.
29. Bing RJ. The metabolism of the heart. Harvey Lect. 1954-55;50:27-70.
30. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093-1129.
31. Russell RR, Taegtmeyer H. Coenzyme A sequestration in rat hearts oxidizing ketone bodies. J Clin Invest. 1992;89:968-973.
32. 13C labeling of citrate released by perfused rat hearts. J Biol Chem. 1997;272:26117-26124.
33. Gibala MJ, Young ME, Taegtmeyer H. Anaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscle. Acta Physiol Scand. 2000;168:657-665.
34. Tirosh R, Mishor T, Pinson A. Glucose is essential for the initiation of fatty acid oxidation in ATP-depleted cultured myocytes. Mol Cell Biochem. 1996;162:159-163.
35. Taegtmeyer H. The failing heart [letter]. N Engl J Med. 2007;356:2545-2546.
36. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest. 1985;76:1819-1827.
37. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. J Clin Invest. 1988;82:2017-2025.
38. McGarry JD, Mills SE, Long CS, Foster DW. Observations on the affinity for carnitine and malonyl-CoA sensitivity of carnitine palmitoyl transferase I in animal and human tissues: demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J. 1983;214:21-28.
39. Ussher JR, Lopaschuk GD. The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc Res. 2008;79:259-268.
40. Goodwin GW, Taegtmeyer H. Regulation of fatty acid oxidation of the heart by MCD and ACC during contractile stimulation. Am J Physiol. 1999;277:E772-E777.
41. Chen TM, Goodwin GW, Guthrie PH, Taegtmeyer H. Effects of insulin on glucose uptake by rat hearts during and after coronary flow reduction. Am J Physiol. 1997;273:H2170-H2177.
42. Nguyen VT, Mossberg KA, Tewson TJ, et al. Temporal analysis of myocardial glucose metabolism by 2-[18F]fluoro-2-deoxy-D-glucose. Am J Physiol. 1990;259:H1022-H1031.
43. Sokoloff L, Reivich M, Kennedy C, et al. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897-916.
44. Hariharan R, Bray M, Ganim R, Doenst T, Goodwin GW, Taegtmeyer H. Fundamental limitations of [18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation. 1995;91:2435-2444.
45. 18F]2-deoxy-2-fluoroglucose in reperfused rat heart muscle. Circulation. 1998;97:2454-2462.
46. Bøtker HE, Goodwin GW, Holden JE, Doenst T, Gjedde A, Taegtmeyer H. Myocardial glucose uptake measured with fluorodeoxyglucose: a proposed method to account for variable lumped constants. J Nucl Med. 1999;40:1186-1196.
47. 18F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation. Nucl Med Biol. 2000;27:221-231.
48. Dence CS, Herrero P, Schwarz SW, Mach RH, Gropler RJ, Welch MJ. Imaging myocardium enzymatic pathways with carbon-11 radiotracers. Methods Enzymol. 2004;385:286-315.
49. Knuuti MJ, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron-emission tomography. J Nucl Med. 1992;33:1255-1262.
50. Knuuti MJ, Yki-Jarvinen H, Voipio-Pulkki LM, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med. 1994;35:989-998.
51. Opie L. Fuels: aerobic and anaerobic metabolism. In: The Heart: Physiology, from Cell to Circulation. Philadelphia, PA: Lippincott Raven; 1998:295.
52. Depre C, Vanoverschelde JL, Melin JA, et al. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol. 1995;268:H1265-H1275.
53. Vanoverschelde JL, Wijns W, Borgers M, et al. Chronic myocardial hibernation in humans: from bedside to bench. Circulation. 1997;95:1961-1971.
54. Camici PG, Wijns W, Borgers M, et al. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation. 1997;96:3205-3214.
55. 11C- hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med. 2005;46:1368-1374.
56. Berry JJ, Baker JA, Pieper KS, HansonMW, Hoffman JM, Coleman RE. The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. J Nucl Med. 1991;32:1518-1525.
57. 13N-glutamate uptake in patients with coronary artery disease. J Am Coll Cardiol. 1988;11:549-556.
58. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
59. Knuuti J. PET imaging in the heart and skeletal muscle: an overview. In: Gropler RJ, Glover DK, Sinusas AJ, Taegtmeyer H, eds. Cardiovascular Molecular Imaging. New York, NY: Informa Healthcare USA, Inc.; 2007:319-324.
60. Stone CK, Holden JE, Stanley W, Perlman SB. Effect of nicotinic acid on exogenous myocardial glucose utilization. J Nucl Med. 1995;36:996-1002.
61. Depre C, Vatner SF. Mechanisms of cell survival in myocardial hibernation. Trends Cardiovasc Med. 2005;15:101-110.
62. Taegtmeyer H. Multiple roles of cardiac metabolism: new opportunities for imaging the physiology of the heart. In: Gropler RJ, Glover DK, Sinusas AJ, Taegtmeyer H, eds. Cardiovascular Molecular Imaging. New York, NY: Informa Healthcare USA, Inc.; 2007:309-318.
63. Opie LH, Sack MN. Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning. J Mol Cell Cardiol. 2002;34:1077-1089.
64. Taegtmeyer H, Dilsizian V. Imaging myocardial metabolism and ischemic memory. Natl Clin Pract Cardiovasc Med. 2008;5(suppl 2):S42-S48.
65. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res. 2008;103:919-928.
66. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev. 2007;12:331-343.
67. Mäki M, Luotolahti M, Nuutila P, et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation. 1996;93:1658-1666.
68. Depre C, Vanoverschelde JL, Gerber B, Borgers M, Melin JA, Dion R. Correlation of functional recovery with myocardial blood flow, glucose uptake, and morphologic features in patients with chronic left ventricular ischemic dysfunction undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1997;113:371-378.
69. Depre C, Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc Res. 2000;45:538-548.
70. Young ME, Guthrie PH, Razeghi P, et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes. 2002;51:2587-2595.
71. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692-1700.
72. Golfman LS, Wilson CR, Sharma S, et al. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab. 2005;289:E328-E336.
73. Harmancey R, Wilson CR, Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension. 2008;52:181-187.
74. Brookheart RT, Michel CI, Schaffer JE. As a matter of fat. Cell Metab. 2009;10:9-12.
75. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999;276:E977-E989.
76. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417-423.
77. 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-1175.
78. Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793-1799.
79. Lamb HJ, Smit JW, van der Meer RW, et al. Metabolic MRI of myocardial and hepatic triglyceride content in response to nutritional interventions. Curr Opin Clin Nutr Metab Care. 2008;11:573-579.
80. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101:759-767.